About: Short and long term impacts of COVID-19 on the pharmaceutical sector

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Short and long term impacts of COVID-19 on the pharmaceutical sector Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Short and long term impacts of COVID-19 on the pharmaceutical sector
Creator	Ayati, Nayyereh Nikfar, Shekoufeh Saiyarsarai, Parisa
Source	Medline; PMC
abstract	BACKGROUND: The novel coronavirus disease 2019 (COVID-19) was characterized as a global pandemic by the WHO on March 11th, 2020. This pandemic had major effects on the health market, the pharmaceutical sector, and was associated with considerable impacts; which may appear in short and long-term time-horizon and need identification and appropriate planning to reduce their socio-economic burden. OBJECTIVES: Current short communication study assessed pharmaceutical market crisis during the COVID-19 era; discussing short- and long-term impacts of the pandemic on the pharmaceutical sector. RESULTS: Short-term impacts of COVID-19 pandemic includes demand changes, regulation revisions, research and development process changes and the shift towards tele-communication and tele-medicine. In addition, industry growth slow-down, approval delays, moving towards self-sufficiency in pharm-production supply chain and trend changes in consumption of health-market products along with ethical dilemma could be anticipated as long-term impacts of COVID-19 pandemic on pharmaceutical sector in both global and local levels. CONCLUSION: The pandemic of COVID-19 poses considerable crisis on the health markets, including the pharmaceutical sector; and identification of these effects, may guide policy-makers towards more evidence-informed planning to overcome accompanying challenges. [Figure: see text]
has issue date	2020-07-03(xsd:dateTime)
bibo:doi	10.1007/s40199-020-00358-5
bibo:pmid	32617864
has license	no-cc
sha1sum (hex)	daf8c1d8944dabc8ba6c020703e6af5e2653016f
schema:url	https://doi.org/10.1007/s40199-020-00358-5
resource representing a document's title	Short and long term impacts of COVID-19 on the pharmaceutical sector
has PubMed Central identifier	PMC7332346
has PubMed identifier	32617864
schema:publication	Daru
resource representing a document's body	covid:daf8c1d8944dabc8ba6c020703e6af5e2653016f#body_text
is schema:about of	named entity 'planning' named entity 'pandemic' named entity 'pandemic' named entity 'COVID-19' named entity '11TH' named entity 'PLANNING' named entity 'PANDEMIC' named entity 'NEED' named entity 'STUDY' named entity 'COVID-19' named entity 'ASSOCIATED WITH' named entity 'CRISIS' named entity 'IMPACTS' named entity 'ECONOMIC BURDEN' named entity 'INCLUDES' named entity 'CHANGES' named entity 'health' named entity 'Current' named entity 'Background' named entity 'levels' named entity 'global' named entity 'coronavirus disease 2019' named entity 'COVID-19' named entity 'pharmaceutical sector' named entity 'ethical dilemma' named entity 'socio-economic' named entity 'long-term' named entity 'WHO' named entity 'long term' named entity 'development' named entity 'Iran' named entity 'pharmaceutical industry' named entity 'health-care' named entity 'prescription medicines' named entity 'anxiety' named entity 'vaccines' named entity 'Favipiravir' named entity 'intellectual property laws' named entity 'Medical Devices' named entity 'COVID-19 outbreak' named entity 'food and drug administration' named entity 'India' named entity 'March 2020' named entity 'self-sufficiency' named entity 'fentanyl' named entity 'economic crisis' named entity 'raw materials' named entity 'pharmaceutical companies' named entity 'registered clinical trials' named entity 'dexmedetomidine' named entity 'dobutamine' named entity 'hypertension' named entity 'Iran' named entity 'prescription medicines' named entity 'currency' named entity 'pharmaceutical sector' named entity 'pharmacy' named entity 'FDA' named entity 'COVID' named entity 'drug development' named entity 'European Commission' named entity 'mental health' named entity 'IFDA' named entity 'dopamine' named entity 'doxycycline' named entity 'pneumonia' named entity 'Iran' named entity 'research and development' named entity 'ceftriaxone' named entity 'lopinavir/ritonavir' named entity 'chloroquine' named entity 'self-sufficiency' named entity 'Induced demand' named entity 'PPE' named entity 'COVID' named entity 'Iran' named entity 'Remdesivir' named entity 'prescription medicine' named entity 'price control'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software